Details of the Drug
General Information of Drug (ID: DMOXQ3N)
Drug Name |
N-Omega-Hydroxy-L-Arginine
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
N-omega-Hydroxy-L-arginine; NG-Hydroxy-L-arginine acetate; CHEBI:43088; FQWRAVYMZULPNK-BYPYZUCNSA-N; N(omega)-hydroxy-L-arginine; L-hydroxyarginine; N(5)-(N-hydroxycarbamimidoyl)-L-ornithine; N(5)-[(hydroxyamino)(imino)methyl]-L-ornithine; 53054-07-2; HAR; Nomega-hydroxy-L-arginine; NG-HYDROXY-L-ARGININE; CHEMBL260629; 1hqf; 6-Noha; N(G)-Hydroxy-L-arginine; (e)-n5-[amino(hydroxyamino)methylidene]-l-ornithine; omega-hydroxy-l-arginine; AC1L3XHY; AC1Q5QLG; Lopac-H-7278; Lopac0_000615; SCHEMBL448333
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 1 | Molecular Weight (mw) | 190.2 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | -4.3 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 6 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 5 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 5 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||